23andme joins health tech’s Spacmania
But more traditional device makers seem uninterested in this means of stock market listing.
Medtech deal-making stands firm in difficult times
It takes more than a pandemic to stop medical device companies merging.
Astrazeneca shows megamergers were still possible in 2020
One of the biggest surprises of 2020 was how biopharma M&A emerged relatively unscathed from Covid-19.
